Table 1.
Summary of regimens used for pre- or postoperative chemotherapy in premenopausal women with early-stage breast cancer (n = 50)
| Regimen | Patients n (%) | Cycles | Interval (weeks) | Dose per cycle | ||
|---|---|---|---|---|---|---|
| Cyclophosphamide | Anthracycline | Docetaxel | ||||
| TAC | 23 (46 %) | 6 | 3 | 500 mg/m2 | 50 mg/m2 (A) | 75 mg/m2 |
| FEC | 15 (30 %) | 6 | 3 | 500 mg/m2 | 90 mg/m2 (E) | – |
| TC | 8 (16 %) | 6 | 3 | 600 mg/m2 | – | 75 mg/m2 |
| EC | 2 (4 %) | 6 | 3 | 600 mg/m2 | 90 mg/m2 (E) | – |
| FAC | 1 (2 %) | 6 | 3 | 500 mg/m2 | 50 mg/m2 (A) | – |
| AC | 1 (2 %) | 6 | 3 | 600 mg/m2 | 60 mg/m2 (A) | – |
T Taxotere® (docetaxel), A adriamycin (doxorubicin), C cyclophosphamide, F fluorouracil, E epirubicin